|Podcasts|September 20, 2022
The Oncologist: Patient Conversation Must Include Clinical Trials
Author(s)Lisa Henderson, Andy Studna, Senior Editor
Dr. Shalaan Beg, VP of Oncology for Science 37, discusses his approach to reducing the time to trial activation at an NCI designated cancer center, how to ensure a diverse representation in clinical trials, and his opinion on decentralized and hybrid trials.
This podcast sponosored by
Related Content
Trending on Applied Clinical Trials Online
1
Curavit Acquires Lindus Health Clinical Research Organization Assets to Expand US and European Trial Operations
2
When the Slack Runs Out: AI and the CRO Operating Model
3
What Needs to Be True Across Sponsors, Sites, and Regulators for Operation TrialBlazer to Succeed
4
ACT Brief: Trial Failures as Administrative Problems, CRO Consolidation for Global Trial Reach, and FDA Approval of First FOP Treatment
5